USA - February 1 2022
With the issuance of its mandate on January 28, 2022, in Catalyst Pharmaceuticals, Inc. v. Becerra, the U.S. Court of Appeals for the Eleventh…
Susan M. Cook, Philip Katz, Komal Nigam
USA - October 1 2021
Recently, the U.S. Food and Drug Administration’s (FDA’s) Office of Orphan Product Development published the four-page final guidance “Interpreting…
Jason F. Conaty, David M. Fox, Komal A. Karnik, Gary Veron
USA - April 27 2021
On April 23, U.S. President Biden signed into law two bills meant to lower prescription drug prices by limiting new drug exclusivity awards and…
Jason F. Conaty, David M. Fox
USA - January 20 2021
On January 5, 2021, President Trump signed into law H.R. 1503, the "Orange Book Transparency Act of 2020," which amends provisions governing the types…
Jason F. Conaty, David M. Fox, Jason A Leonard, Gary Veron
USA - May 10 2019
On Thursday, FDA published the final guidance document, “Determining Whether to Submit an ANDA or a 505(b)(2) Application” that contains minor…
Philip Katz